![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Availability of the Q3 2022 Memorandum for modelling functions
Paris, France – September 28, 2022 – Sanofi introduced immediately that its Q3 2022 Memorandum for modelling functions is out there on the “Investors” web page of the firm’s web site:
https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q3-results-2022
As for every quarter, Sanofi ready this doc to help in the monetary modelling of the Group’s quarterly outcomes. This doc features a reminder on varied non-comparable gadgets and exclusivity losses in addition to the international forex affect and share depend. Sanofi’s third-quarter 2022 outcomes shall be revealed on October 28, 2022.
About Sanofi
We are an modern international healthcare firm, pushed by one goal: we chase the miracles of science to enhance folks’s lives. Our crew, throughout some 100 international locations, is devoted to reworking the follow of drugs by working to show the unattainable into the attainable. We present doubtlessly life-changing remedy choices and life-saving vaccine safety to hundreds of thousands of folks globally, whereas placing sustainability and social duty at the heart of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]
Sally Bain | + 1 617 834 6026 | [email protected]
Nicolas Obrist | + 33 6 77 21 27 55 | [email protected]
Victor Rouault | + 33 6 70 93 71 40 | [email protected]
Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | [email protected]
Arnaud Delépine | + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt | + 33 6 40 56 92 21 | [email protected]
Felix Lauscher | + 1 908 612 7239 | [email protected]
Priya Nanduri | + 1 617 764 6418 | [email protected]
Nathalie Pham | + 33 7 85 93 30 17 | [email protected]
Sanofi Forward-Looking Statements
This press launch comprises forward-looking statements as outlined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that aren’t historic details. These statements embrace projections and estimates and their underlying assumptions, statements concerning plans, aims, intentions and expectations with respect to future monetary outcomes, occasions, operations, providers, product growth and potential, and statements concerning future efficiency. Forward-looking statements are typically recognized by the phrases “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and comparable expressions. Although Sanofi’s administration believes that the expectations mirrored in such forward-looking statements are affordable, buyers are cautioned that forward-looking info and statements are topic to varied dangers and uncertainties, many of that are tough to foretell and usually past the management of Sanofi, that might trigger precise outcomes and developments to vary materially from these expressed in, or implied or projected by, the forward-looking info and statements. These dangers and uncertainties embrace amongst different issues, the uncertainties inherent in analysis and growth, future scientific information and evaluation, together with submit advertising and marketing, choices by regulatory authorities, resembling the FDA or the EMA, concerning whether or not and when to approve any drug, system or organic software which may be filed for any such product candidates in addition to their choices concerning labelling and different issues that might have an effect on the availability or industrial potential of such product candidates, the undeniable fact that product candidates if authorized is probably not commercially profitable, the future approval and industrial success of therapeutic options, Sanofi’s potential to profit from exterior development alternatives, to finish associated transactions and/or acquire regulatory clearances, dangers related to mental property and any associated pending or future litigation and the final end result of such litigation, developments in change charges and prevailing rates of interest, unstable financial and market circumstances, price containment initiatives and subsequent adjustments thereto, and the affect that COVID-19 can have on us, our prospects, suppliers, distributors, and different business companions, and the monetary situation of anyone of them, in addition to on our workers and on the international economy as an entire. Any materials impact of COVID-19 on any of the foregoing might additionally adversely affect us. This state of affairs is altering quickly and extra impacts might come up of which we aren’t at the moment conscious and will exacerbate different beforehand recognized dangers. The dangers and uncertainties additionally embrace the uncertainties mentioned or recognized in the public filings with the SEC and the AMF made by Sanofi, together with these listed beneath “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the yr ended December 31, 2021. Other than as required by relevant legislation, Sanofi doesn’t undertake any obligation to replace or revise any forward-looking info or statements.
